In day-to-day practice, based on the immunohistochemical expression of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), breast cancer is classified into various molecular subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.